Docetaxel rechallenge versus cabazitaxel in patients previously treated with docetaxel for metastatic castrate-resistant prostate cancer (mCRPC).
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Pedro C. Barata, June Corrigan, John Culnan, Karlynn N Dulberger, Jennifer La, Elliot Akama-Garren, Clark DuMontier, Jason Edward Hansen, Rhonda L. Bitting, Heather H. Cheng, Matthew R. Cooperberg, Tanya B. Dorff, Susan Halabi, Stacy Loeb, David M. Nanus, Chong-xian Pan, Martin W. Schoen, Nathanael Fillmore, Channing Judith Paller, Matthew Rettig, PROFOUND-VET Investigators Group
Institutions: University Hospitals of Cleveland, University Hospitals Seidman Cancer Center, VA Boston Healthcare System, Harvard University, Brigham and Women's Hospital, University of New England, Durham VA Medical Center, University of Washington, University of California, San Francisco, City Of Hope National Medical Center, Duke University, Duke Medical Center, NYU Langone Health, NewYork–Presbyterian Hospital, Weill Cornell Medicine, Saint Louis University, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, University of California, Los Angeles
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4407699973